Market Report Source

Overview

Introduction

Tanox identifies and develops therapeutic monoclonal antibodies to address significant unmet medical needs in the areas of immunology, infectious diseases and cancer. In January 2007, the stockholders of Tanox approved the merger with Genentech for $20 per share for a total cash value of approximately $919 million

Scope

Contains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors Includes information on suppliers/ partners, shareholding structure and key employees with biographies

Highlights

Tanox is a biopharmaceutical company focused on discovering and developing therapeutic monoclonal antibodies that influence or are derived from the immune system. The company’s therapeutic emphasis is on the areas of immunology (asthma/allergy and autoimmune diseases), infectious diseases, and oncology. Tanox derives its revenues from royalties, license fees, development and manufacturing right, and profit sharing for its humanized monoclonal antibody product, Xolair.

Reasons to Purchase

Access all the important information and analysis on the company in a single report Understand company’s strengths, weaknesses, opportunities and threats along with business strategy and value chain Gain access to company’s adjusted five year financial data along with key ratios and market capitalization.

Table of Contents

Overview
Catalyst
Summary
Table of Contents
Table of figures
Table of tables
Company Structure
Company Overview and Key Facts
Business Description
Landmark Products & Services
Xolair
History
M&A History
Genentech
Locations and Subsidiaries
Company Financials
Stock Market Performance
P&L
Balance Sheet
Cash Flow
Business Segment Performance
Products & Services
Marketed Products
Xolair
Pipeline Products
Collaboration Pipeline
TNX 355
TNX 650
TNX 234
TNX 559
AC Forecast Product Sales
Competitors and Strategic Businesss Relationships
Top Competitors
Key Suppliers
Key Clients
Shareholding Structure
Strategy
Corporate Strategy
SWOT Analysis
Overview
Strengths
Xolair
Weaknesses
Weak product pipeline
Opportunities
Merger with Genentech
Growing HIV Market
Threats
Competitive threat
Regulatory challenges
Value Chain Analysis
Overview
Discovery and Product Development
Manufacturing
Scorecard
Overview
Scorecard Analysis
Financial and Operational Overview
Financial and Operational Overview
Appendix
Ask the analyst
Datamonitor consulting
Disclaimer

List of Tables
Table 1: Tanox – Key Facts
Table 2: Tanox – Other Locations and Subsidiaries
Table 3: Tanox – Year-End Share Price and Market Capitalization, 2002-2006 ($)
Table 4: Tanox – Key Events Impacting Share Price Performance
Table 5: Tanox – Operating Revenue/Cost Analysis, 2002-2006 ($ Mn)
Table 6: Tanox – Operating Cost Ratio Analysis, 2002-2006 (% of total revenues)
Table 7: Tanox – Balance Sheet, 2002-2006 ($ Mn)
Table 8: Tanox – Cash Flow, 2002-2006 ($ Mn)
Table 9: Tanox – Revenue Breakdown, 2002-2006 ($ Mn)
Table 10: Tanox – Marketed Products
Table 11: Tanox – Collaboration Pipeline Products
Table 12: Tanox – Forecast Sales, 2006-2010 ($ Mn)
Table 13: Tanox – Top Competitors
Table 14: Tanox – Key Suppliers
Table 15: Tanox – Key Clients
Table 16: Tanox – Key Shareholders
Table 17: Tanox – SWOT Analysis Summary
Table 18: Tanox – Value Chain Analysis
Table 19: Tanox – Scorecard
Table 20: Tanox – Financial and Operational Overview

List of Figures
Figure 1: Tanox – Operating Revenue/Cost Analysis, 2002-2006 ($ Mn)
Figure 2: Tanox – Key Strategic Revenues, 2002-2006 ($ Mn)
Figure 3: Tanox – Key Strategic Revenues, 2006-2010 ($ Mn)